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Summary Dual photon absorptiometry (DPA) has been used to measure the effect of short and medium-
term administration of tamoxifen on bone density in the axial skeleton of women with mastalgia. This
provided a unique opportunity to monitor the effect of this 'anti-oestrogenic' agent in predominantly
premenopausal women, not suffering from malignancy. In addition, plasma levels of calcium, phosphate,
alkaline phosphatase and serum levels of oesteocalcin (GLA) have been assayed, both before and after 3
months of starting either tamoxifen or placebo treatment. No significant alterations in bone density were
seen. Osteocalcin, alkaline phosphatase and electrolytes were unchanged and there was no dose response
observed in women receiving either 10mg or 20mg of tamoxifen. Although possessing anti-oestrogenic
properties, tamoxifen is also a partial agonist. Administration for the short periods does not measurably
influence spinal or femoral bone density and thus the agent can probably be given safely for the short-term
treatment of mastalgia.
The anti-oestrogenic agent tamoxifen has proved to be of
value in the treatment of patients with advanced breast
cancer and also as adjuvant therapy for those with operable
disease (Cole et al., 1971; NATO, 1985). In women with
advanced disease similar remissions are achieved with either
oestrogens or tamoxifen, but the latter agent is associated
with a greatly diminished incidence of toxicity (Rubens,
1986). Because of the observed lack of severe side-effects it
has been proposed that tamoxifen might be of benefit to
hyper-oestrogenised women who could be at increased risk
of developing breast cancer (Cuzick et al., 1986). However,
before altering the hormonal milieu of ostensibly normal
women it has to be determined whether the administration
of tamoxifen leads to the development of conditions such as
osteoporosis and ischaemic heart disease, which can follow
the natural oestrogen withdrawal at the menopause.
Oestrogens play an important role in the regulation of
bone turnover in women. Natural or artificial menopause is
followed by an accelerated rate of bone loss mainly affecting
trabecular bone (Albright et al., 1941). The mechanism by
which oestrogens exert their influence is unknown but there
is convincing evidence that post-menopausal bone loss can
be abolished by the administration of exogenous oestrogen
(Lindsay et al., 1976). Gotfredsen et al. (1984) studied
premenopausal women with early breast cancer treated by
radical mastectomy and who subsequently received either
tamoxifen or placebo. They measured bone mineral content
by single photon absorptiometry of distal forearm and found
a reduction in BMC in both tamoxifen and placebo treated
groups. This reduction in bone mineral content was no
greater among those receiving tamoxifen than among the
placebo group. However, cortical and trabecular bone
exhibit different patterns of loss and the clinically important
sites of osteoporotic fractures in later life, spine and femoral
neck, are predominantly trabecular. Riggs et al. (1981)
measured both spinal BMC by dual photon absorptiometry
(DPA) and forearm density by single photon absorptiometry
(SPA). They found a linear loss of BMC in the spine of
premenopausal women whereas SPA measurements of
forearm BMC showed no changes until after the age of 50.
It has recently been demonstrated in a controlled clinical
trial that tamoxifen is effective in the treatment of cyclical
mastalgia in premenopausal women (Fentiman et al., 1986).
The first clinical trial compared a placebo treated group with
a tamoxifen group, and the second trial examined different
dosages and durations of tamoxifen treatment (Fentiman et
al., 1986). These have provided an opportunity to study the
short and medium-term effects of tamoxifen on bone mineral
metabolism in premenopausal patients who are not suffering
from malignancy.
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Patients and methods
Mastalgia patients
All women had self-rated moderate or severe mastalgia, of
either cyclical or non-cyclical type which had been present
for six months or more.
Trial 1
Details of the trial design have been published (Fentiman et
al., 1986). Patients received either tamoxifen 20mg daily for
3 months, or placebo (vitamin C) 50mg daily for the same
period. Those whose pain failed to respond were switched to
the alternative therapy for a further 3 months.
Trial 2
This was a factorial design and women received tamoxifen
10mg or 20mg daily for either 3 or 6 months of treatment.
This study demonstrated that dosages of 10mg and 20mg
daily were equally efficacious, although the lower dose was
associated with significantly fewer side-effects. Prolongation
of treatment from 3 to 6 months did not affect the response
rate, nor the relapse rate.
Bone mineral content
BMC of the lumbar spine (L2-4) and femoral neck were
measured by dual photon absorptiometry (DPA) using a
Novo BMC-LAB 22A system with a 153Gd source. BMC
was expressed in terms of grams of hydroxyapatite per unit
projected area of bone (gHAcm-2). Measurements were
made before treatment started and 3 months later when the
patients were receiving either tamoxifen or placebo. Among
those patients who had more prolonged treatment, DPA
scans were performed at 6 months and at approximately 2
years after starting treatment.
Biochemical analysis
Blood was taken before entry to the study and 3 months
later when on treatment. Calcium, phosphate, albumin and
alkaline phosphatase were measured routinely using a
Vickers autoanalyser. Osteocalcin was measured by radio-
immunoassay, using serum samples.
Results
The DPA results for the placebo and tamoxifen groups both
before (baseline) and during treatment (three months) are
shown in Table I. No significant changes in BMC were seen
after 3 months of either placebo or tamoxifen. Similarly, in
Table II the results of administration of 6 months of
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Table I Effect of tamoxifen on bone mineral content of lumbar
spine measured in grams hydroxyapatite per cm2
gHA cm-2
Placebo vs tamoxifen Baseline 3 months
Placebo
(n=10) 1.0 +0.09 1.0 +0.09
Tamoxifen
(n =10) 0.92 +0.06 0.92 +0.06
Values are mean+standard deviation.
Table II Effect of different dosages and duration on bone mineral
content of lumbar spine and femur
Spine Femur
(gHA cm2) (gHA cm-2)
Tamoxifen 10mg daily (n = 10)
Baseline 0.87+0.09 0.76+0.09
3 months 0.87+0.09 0.76+0.10
Tamoxifen 20mg daily (n=8)
Baseline 0.91 +0.09 0.77+0.20
3 months 0.91 +0.09 0.78+0.10
Six months Tamoxifen (n= 10)
Baseline 0.95+0.06 0.81 +0.11
6 months 0.94+0.06 0.81+0.10
Long-term bone mineral measurements were performed in
20 patients, after a median interval of 29 months from date
of entry (range 23-34 months). For all, DPA scans of
lumbar spine were available, and for a subset of 14,
measurements of femoral density were also obtained. The
results are given in Table IV, which shows that there was no
reduction in either measurement, compared with the
baseline. Table IV also gives control data from a normal
population data base of bone mineral measurements of
controls who were age-matched for the tamoxifen group at
the time of follow-up DPA scans. There was no significant
difference (E-fat P>0.1). This strongly suggests that
tamoxifen administration for up to 6 months does not exert
any bone demineralising effect measured up to 3 years later
in premenopausal women with mastalgia.
Discussion
The aim of the study was to determine whether short or
medium-term tamoxifen administration could lead to
detectable changes in bone mineral content of the lumbar
spine and femoral neck. Because of the complexity of
regulation of bone metabolism involving disparate factors
such as age, weight, exercise and endocrine status, data from
controlled trials may be important in determining the effect
of tamoxifen on bone density (Brewer et al., 1983; Alois et
al., 1983; Williams et al., 1982; Daniell, 1976; Schlechte et
Table III The effect of tamoxifen administration of plasma calcium, phosphate, alkaline
phosphatase and osteocalin
Osteocalcin
Ca P04 Alk. phos. (ngml)
(mmol1- ') (mmol1- ' ) (ul- ') (mmoll 1)(mmol) (u
Tam. 10mg Tam. 20mg
Baseline
(n=24) 2.32+0.02 0.93+0.02 144+8.5 2.7+0.2 2.2+0.3
3 months 2.28+0.02 0.88+0.02 125+7.5 2.4+0.2 2.5+0.3
Values are mean+standard error.





Follow-up (median) months 29 29
Baseline 0.9 +0.11 0.75+0.12
Follow-up 0.89+0.11 0.74+0.13
Controls 0.91 +0.21 0.80+0.09
Values are mean+standard deviations.
tamoxifen are shown, with no significant change from the
baseline level.
Patients taking part in the second trial were randomised
to receive either 10mg or 20mg of tamoxifen daily. To
determine whether a dose-response effect on BMC was seen,
the 3-month and baseline DPA scans were compared for
patients receiving the two dosages. As is shown in Table II,
no differences were observed between patients treated with
either dosage of tamoxifen. Levels of calcium, phosphate,
albumin and alkaline phosphatase, both before therapy and
after 3 months' treatment, are shown in Table III. No
significant changes were observed. Table III also shows the
serum levels of osteocalcin both before treatment and after 3
months of tamoxifen at a dosage of 10mg and 20mg daily.
No significant changes in osteocalcin levels were observed.
al., 1983; Reeve et al., 1989; Riggs et al., 1972). The known
actions of tamoxifen are several. The agent acts as an
oestrogen antagonist as measured by blockade of oestradiol
uptake by peripheral receptors (Harper & Walpole, 1967). At
the same time, hepatic synthesis of both sex hormone
binding globulin (SHBG) and cortisol binding globulin
(CBG) is induced, in a manner similar to that following the
administration of exogenous oestrogen (Sakai et al., 1978;
Debruyne et al., 1980). Parallel with these increases in levels
of steroid binding proteins, there is an elevation of total
oestradiol, cortisol and testosterone, although there may be a
reduction in the amount of biologically available steroids
and a reduction in prolactin levels (Caleffi et al., 1988).
Similar oestrogen agonist effects on endocrine function have
been found in patients receiving tamoxifen for mastalgia, in
whom a slight reduction in HDL2 subclass of high density
lipoprotein has been found (Caleffi et al., 1988).
Tamoxifen treatment for up to 6 months has no effect on
bone density in the lumbar spine or femur in a dosage of up
to 20mg daily. Furthermore, when women who had taken
a 6-month course of tamoxifen were assessed 29 months
(median) later, their bone densities did not differ significantly
from a group of age-matched controls. Thus it is unlikely
that tamoxifen does have any deleterious effect on bone
mineral metabolism. These data support the short and
medium-term safety of tamoxifen on bone mineral
metabolism when given to premenopausal women with
breast pain.
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